Abstract: Multikinase inhibitors (MKIs), including the tyrosine kinase inhibitors (TKIs), have rapidly become an established factor in daily (hemato)-oncology practice. Although the oral route of administration offers improved flexibility and convenience for the patient, challenges arise in the use of MKIs. As MKIs are prescribed extensively, patients are at increased risk for (severe) drug-drug interactions (DDIs). As a result of these DDIs, plasma pharmacokinetics of MKIs may vary significantly, thereby leading to high interpatient variability and subsequent risk for increased toxicity or a diminished therapeutic outcome. Most clinically relevant DDIs with MKIs concern altered absorption and metabolism. The absorption of MKIs may be decreased by concomitant use of gastric acid-suppressive agents (e.g. proton pump inhibitors) as many kinase inhibitors show pH-dependent solubility. In addition, DDIs concerning drug (uptake and efflux) transporters may be of significant clinical relevance during MKI therapy. Furthermore, since many MKIs are substrates for cytochrome P450 isoenzymes (CYPs), induction or inhibition with strong CYP inhibitors or inducers may lead to significant alterations in MKI exposure. In conclusion, DDIs are of major concern during MKI therapy and need to be monitored closely in clinical practice. Based on the current knowledge and available literature, practical recommendations for management of these DDIs in clinical practice are presented in this review.
Introduction
Although cancer is still the leading cause of death among men and women worldwide, novel treatment options are rapidly evolving. In order to improve treatment efficacy and minimize toxicity more specific targets have been identified. One of the most promising classes of targeted anticancer agents are the multikinase inhibitors (MKIs), including the tyrosine kinase inhibitors (TKIs). MKIs target specific tyrosine kinases within the tumor cell, where they play a key role in signal transduction, gene transcription, and DNA synthesis. 1 MKIs like osimertinib (for lung cancer) and cabozantinib (for kidney cancer) rapidly gained a place in standard of care treatment for multiple or new indications [e.g. regorafenib in primary liver cancer, after earlier approvals for gastrointestinal stromal tumor (GIST) and colorectal cancer].
MKIs include both small molecule MKIs and large molecule MKIs. In this review we will solely focus on the small molecule MKIs. Small molecule MKIs are administered orally, which gives them a clear advantage over conventional chemotherapy in terms of flexibility and patient convenience. Many MKIs show a narrow therapeutic window, whereas intra-and interpatient exposure is highly variable and multifactorial. [2] [3] [4] Also factors like food, beverages, lifestyle, and pharmacogenetic polymorphisms may alter MKI bioavailability significantly. 5 For example, as MKIs are predominately metabolized through phase I (e.g. CYP enzymes) or phase II enzymes (e.g. UPD-glucuronyltransferases) or almost exclusively by phase II enzymes (e.g. in the case of afatinib), this makes them highly prone for drug-drug interactions (DDIs) involving drug metabolism. 6 Moreover, since cancer patients often use multiple drugs concomitantly with their anticancer therapy, they are even more at risk for DDIs, compared with other patient groups. 7 DDIs can be classified as pharmacodynamic or pharmacokinetic. 8 Pharmacokinetic DDIs are defined as drug interactions regarding drug absorption, metabolism, distribution and elimination leading to altered plasma concentrations of a drug and possible unfavorable outcomes (e.g. increased toxicity and reduced treatment efficacy). A pharmacodynamic interaction is the altered response in terms of toxicity and efficacy when two or more drugs affect similar molecular targets (e.g. membrane receptors). Pharmacodynamic DDIs can be additive, antagonistic or synergistic. For instance, epidermal growth factor receptor (EGFR) kinase inhibitors often show synergistic antitumor effects when combined with chemotherapy. 9 Both the United States Food and Drug Administration (US FDA) and the European Medicines Agency (EMA) present guidelines for the interpretation of DDIs. However, because of discrepancies between recommendations, currently no clear general consensus for the management of DDIs is available. Therefore, the management of DDIs is challenging for clinicians and the need for a general consensus is urgent.
This review article presents an overview of known pharmacokinetic DDIs regarding orally taken MKIs currently approved by the US FDA and EMA. Moreover, if possible, practical recommendations are given for the management of DDIs during MKI therapy in clinical practice.
Methods
We conducted a search in PubMed and the Embase databases for English language studies published until 2 July 2018 for randomized clinical trials, observational studies, and reviews about US FDA and EMA-approved MKIs. We used the following search MESH terms: '(Drug interactions) OR (Drug combination) AND (Drug name) ' . In Embase, we used 'clinical studies', 'humans' and 'only in English' as additional search limits. The search results were manually screened for relevance. In addition, all MKI (US FDA and EMA) assessment reports were screened on the latest updates regarding DDIs in the scientific updates available at the EMA and US FDA website until 2 July 2018. We included clinical drug-drug interaction studies in human and preclinical pharmacokinetic studies investigating possible interactions. We excluded studies which did not focus on pharmacokinetics or drug interactions. Clinical relevance of the interaction was scored on the basis of the US FDA-classification of the effect of drug interactions and the level of available evidence as a 'major', 'moderate' or 'minor' interaction. If there was no clinical pharmacokinetic study performed, the interaction potential was estimated on the basis of the inhibitory concentration or pKa and the advice in the assessment reports. 10 
Absorption

Intragastric pH
The absorption of MKIs can be significantly affected by altered intragastric pH. When intragastric pH is elevated (e.g. due to proton pump inhibitors; PPIs), the MKI solubility, bioavailability, and eventually treatment efficacy may be significantly influenced ( Figure 1 ). 8, [11] [12] [13] The impact of this 'pH effect' is highly variable per MKI and the clinical relevance of the DDI between MKIs and acid-suppressive agents (e.g. PPIs, H 2 -antagonists and antacids) must be assessed on an individual basis. A complete overview can be found in Table 1 . Indecisive guidelines and the fact that 20-30% of all cancer patients have an indication for the use of acid-suppressive agents (ASAs) complicate the management of this DDI. 36 The general consensus is, if possible, to avoid the combination between MKIs and ASAs. 37 However, if there is a distinct indication for an ASA (e.g. Barrett's esophagus), a clear and practical advice to manage the DDI between MKIs and ASAs is essential to safeguard optimal MKI therapy. Based on the pharmacokinetics and pharmacodynamics of both MKIs and ASAs, practical advice can be given for the management of the DDI between MKIs and PPIs, H 2 -antagonists (H 2 As) and antacids (see Figure 1 and Table  1 ). 13 This advice may be extrapolated to newly introduced MKIs with a known or suspected drug interaction with gastric suppressive agents journals.sagepub.com/home/tam 3 and thus with a great impact of the 'pH effect' as mentioned in Figure 1 and Table 1 .
MKIs and PPIs. Since PPIs do not elevate intragastric pH over the full 24 h-range, a window of relatively low intragastric pH may be used to manage the DDI. 38 If there is a hard indication for PPI use, MKIs should be taken at least 2 h before the PPI in the morning in a once-daily regimen, since MKIs can be absorbed completely within this window. 13, 38 Another possibility is to administer a MKI with an acidic beverage such as cola (pH = 2.5) to manage the DDI, since the acidic beverage temporarily decreases stomach pH resulting in better MKI solubility and absorption. 23 Furthermore, the influence of other acidic beverages [e.g. sprite (pH = 3.4) or orange juice (pH = 3.
3)] on the absorption of MKIs has not been studied yet.
MKIs and H 2 -antagonists. Since most H 2 -antagonists show a short plasma half-life and are administered in a twice daily regimen (e.g. ranitidine), MKIs should be taken at least 2 h before or 10 h after the H 2 -antagonist intake according to US FDA and EMA guidelines. 14, 15 Management MKIs and antacids. Antacids are relatively short-acting agents (e.g. magnesium hydroxide). MKIs should be administered at least 2 h before, or 4 h after antacid intake, to manage this DDI. 14, 15 Drug transporters and intestinal enzymes As mentioned previously, MKI absorption is a multifactorial process mediated and affected by passive diffusion, active transport through multiple drug transporters, and intestinal metabolism. 7 The activity of these drug transporters and intestinal enzymes may significantly influence MKI bioavailability.
Drug transporters are located throughout the body, especially in the gut, bile ducts, kidneys and the blood-brain barrier (Figure 2 ). 39 The US FDA states: 'membrane transporters can have clinically relevant effects on the pharmacokinetics and pharmacodynamics of a drug in various organs and tissues by controlling its absorption, distribution, and elimination. In contrast to drug metabolizing enzymes that are largely expressed in the liver and ASA, acid-suppressive agent; DDI, drug-drug interaction; MKI, multikinase. BCRP, breast cancer resistance protein (ABCG2); CYP, cytochrome P450 iso-enzyme, MATE, multi-antimicrobial extrusion protein; MRP, multidrug resistance associated protein; OAT, organic anion transporters; OATP, organic anion transporting peptides; OCT, organic cation transporters; P-gp, P-glycoprotein (ABCB1); UGT, UDP-glucuronosyltransferase.
into the portal blood stream and metabolized by hepatocytes, secreted into the bile and eventually are reabsorbed after secretion of bile in the gut lumen. 40 In this multi-step process drug transporters like P-gp and BCRP play a significant role.
Other drug efflux transporters that may influence MKI bioavailability are the multidrug resistance protein subfamily (ATP-binding cassette subfamily C member 1 to 12, ABCC1 to 12, like MRP1) and the multi-antimicrobial extrusion protein (MATE), while several uptake transporters may be involved as well [e.g. organic anion transporting peptides (OATPs), organic anion transporters (OATs), and organic cation transporters (OCTs), see Figure 2 ].
Many drugs are known P-gp inhibitors (e.g. verapamil) or act as a strong P-gp-inducer (e.g. rifampicin). Drugs like cyclosporine, an inhibitor of several OATPs (e.g. OATP1B1 and BCRP) and cimetidine (OCT2 inhibitor) may influence other drug transporters as well. 41 For example, nintedanib showed a decrease in both area under the curve (AUC) and maximum concentration (C max ) when co-administered with rifampicin. Since nintedanib is almost exclusively metabolized by phase II enzymes, this effect on AUC and C max is most likely due to P-gp induction. 42 In general the use of strong P-gp or BCRP inhibitors or inducers is discouraged when MKIs are substrates for these transporters. Furthermore, many MKIs show inhibition of several drug transporters by themselves (Table 2) . 14, 15, 18, 21, 35, 41, [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] When a MKI acts like an inhibitor of these transporters and is co-administered with drug transporter substrates with a narrow therapeutic window (e.g. digoxin), close monitoring of side effects (e.g. severe arrhythmia for digoxin) is warranted. For some MKIs the clinical relevance of DDIs regarding drug transporters is negligible and the combination with inhibitory or inducing compounds is considered to be well tolerated (e.g. bosutinib). 14, 15 In contrast with the above mentioned unwanted adverse effects, mostly found in preclinical studies, DDIs concerning drug transporters and MKIs may also be used in a beneficial way. For example, MKIs may potentially increase chemotherapy concentrations through P-gp or BCRP inhibition (e.g. increased paclitaxel plasma concentration resulting from P-gp inhibition by nilotinib or increased nilotinib concentrations as a result of P-gp inhibition by imatinib). 60, 61 In conclusion, we found only a limited number of clinical studies, which investigated the effects of inhibition or induction of drug transporters by MKIs, since this is a relatively novel field of DDI research. Combinations between strong drug transporter inhibitory or inducing compounds should be avoided for most MKIs as mentioned in Table 2 .
Intestinal metabolism
Another important factor in drug absorption is intestinal metabolism. Many MKIs are metabolized in the gut wall through intestinal CYP3A4, which is often in close proximity of drug transporters, such as P-gp. When a MKI is given concomitantly with an intestinal CYP3A4 inducer (e.g. rifampicin) or inhibitor (e.g. grapefruit juice) this may significantly change MKI bioavailability. 62 However, in contrast, Van Erp and colleagues failed to show a significant increase in sunitinib exposure, when co-administered with grapefruit juice. 63 Moreover, since many MKIs undergo extensive first-pass metabolism and are thus dependent of both intestinal and hepatic metabolism, it is difficult to determine whether intestinal metabolism or hepatic metabolism is the main contributor to an altered drug bioavailability.
Metabolism
In the liver, MKIs are predominately metabolized by CYP enzymes into either active or inactive metabolites. For some MKIs, like nintedanib, phase II metabolism through UDPglycosyltransferases (UGTs), glutathione S-transferases and sulfotransferases (SULTs) is dominant in their metabolism. 6, 64, 65 Inhibition or induction of these phase I and II enzymes by coadministered medication may lead to either (severe) toxicity or loss of effective MKI therapy, respectively.
As DDIs with strong CYP3A4 inhibitors and inducers (e.g. ketoconazole and rifampicin, respectively) play a significant role in MKI therapy, they are usually well described and clear recommendations for the management of these DDIs are presented in the assessment report. There are many (strong) inducers or inhibitors of CYP enzymes for which a complete overview can be found at the FDA and EMA websites. 41, 66 Moreover, some MKIs (e.g. imatinib, pazopanib) also displayed inhibitory or inducing activity by themselves. [67] [68] [69] [70] The general advice is to avoid concomitant administration with strong inhibitors or inducers of CYP enzymes. If this is not possible, a MKI dose 
Interactions with novel MKIs
In the last decade there has been a significant increase in the development of and treatment with MKIs resulting in more than a doubling of registered MKIs in the past 5 years. Earlier, we described the DDIs with MKIs which were approved before 1 August 2013. 6 Here, we give an extensive overview of the DDI potential and management of the novel MKIs, which have been approved after August 2013. A complete overview including all (new and older) MKIs is presented in Tables 1-3 .
Afatinib. Afatinib is used in the treatment of nonsmall cell lung cancer (NSCLC). It is a substrate of P-gp and BCRP and is mainly metabolized through enzyme-catalyzed Michael adduct formation (phase II) and only in a minor extent to phase I enzymes like CYP3A4 and FMO (2%). 14, 15 Concomitant administration with ritonavir (a P-gp inhibitor) showed a 48% increase in AUC and 39% increase in C max. 43 Treatment with a potent P-gp inducer (rifampicin) prior to singledose afatinib showed a moderate effect on both afatinib AUC and C max (34% and 22% decrease respectively). 43 When afatinib is administered with strong P-gp and BCRP inhibitors, staggered dosing may be used, preferably 6 h or 12 h apart from afatinib intake. When afatinib is administered with strong P-gp inducers the dose may be increased with 10 mg with close monitoring of side effects. Administration with strong CYP inducers or inhibitors is considered safe, since no CYP enzymes are involved in afatinib metabolism. Furthermore in vitro studies showed afatinib itself to be an inhibitor of P-gp and BCRP, so close monitoring of side effects when administered with substrates for these transporters with a narrow therapeutic window is recommended. 14, 15 Alectinib. The anaplastic lymphoma kinase (ALK) inhibitor alectinib is used in the treatment of metastatic lung cancer. Alectinib as well as its M4 metabolite are considered equally active. Alectinib is primary metabolized by CYP3A4. 14, 15 Co-administration with the strong CYP3A4 inhibitor posaconazole resulted in a 75% increase of AUC, while co-administration with rifampicin led to a 73% decrease in alectinib AUC. 44 Since alectinib and M4 are equally active, a dose modification is not necessary (unless patients experience a significant increase in toxicity) when alectinib is administered with strong inhibitors or inducers of CYP3A4. Since alectinib is a P-gp and BCRP inhibitor, close monitoring of side effects of these substrates is recommended, especially for drugs with a narrow therapeutic window (e.g. digoxin).
Bosutinib. Bosutinib is used in the treatment of chronic myeloid leukemia (CML). Although bosutinib is a P-gp substrate and inhibitor, DDIs are not likely to appear, since clinical studies demonstrated no significant effect on dabigatran (P-gp substrate) or bosutinib (when administered with the P-gp inhibitor lansoprazole) pharmacokinetics. 18, 45 Therefore no bosutinib dose reductions are necessary, when administered with strong P-gp inducers or inhibitors. Bosutinib is mainly metabolized through CYP3A4 and coadministration with the strong inhibitor ketoconazole resulted in 420% increase in C max and 760% increase in AUC. 74 Administration with rifampicin showed a significant 86% reduction in C max and a 92% decrease in AUC of bosutinib. Administration with the moderate inhibitor aprepitant also showed an increase in AUC and C max. 73 In conclusion; strong inhibitors or inducers of CYP3A4 must be avoided or a gradual 20% dose reduction should be applied, when co-administered with strong inhibitors of CYP3A4. Increasing the bosutinib dose is not useful, when co-administered with strong CYP3A4 inducers, since a maximal tolerated bosutinib dose of 600 mg is often not sufficient to compensate for the relatively large loss of exposure. 14, 15 Cabozantinib. Cabozantinib is used in the treatment of medullary thyroid carcinoma and renal cell carcinoma (RCC). Since cabozantinib is a P-gp and BCRP inhibitor, close monitoring of side effects of substrates with a narrow therapeutic window is recommended when co-administered with cabozantinib. 14,15 A study with ketoconazole and rifampicin showed a significant change in AUC (38% increase and 77% decrease, respectively). 75 There was no significant effect of cabozantinib on rosiglitazone (a CYP2C8 substrate) plasma pharmacokinetics, indicating no inhibitory effect on CYP2C8 in contrast to the in vitro data. 75 The product label recommends minimizing the risk of a 15 Tan and colleagues 83 Phenytoin or carbamazepine 50% decrease 30% decrease Cobimetinib. Cobimetinib is a BRAF inhibitor used in the treatment of melanoma. It is a substrate for P-gp and inhibits BCRP, OATP1B1, OATP1B3, and OCT1. 14, 15 Therefore, close monitoring of side effects is warranted when cobimetinib is administered with BCRP (e.g. rosuvastatin), OATP1B1, OATP1B3 (e.g. atorvastatin) or OCT1 substrates (metformin) with a narrow therapeutic window. Cobimetinib is primarily metabolized by CYP3A4 and UGT2B7. When co-administered with itraconazole 570% and 220% increase in AUC and C max was seen, respectively. 14, 15 A physiologically based pharmacokinetic (PBPK) model demonstrated rifampicin to decrease cobimetinib AUC by 83% and C max by 63%. 76 So, the co-administration with strong inhibitors or inducers of CYP3A4 and P-gp must be avoided. However, rabeprazole (a P-gp inhibitor) showed no effects on the pharmacokinetics of cobimetinib. 21 If concomitant use of cobimetinib and strong CYP3A4 inhibitors is unavoidable, the cobimetinib dose should be decreased with 20 mg (33%) following a step-by-step approach. Furthermore, since cobimetinib is a CYP1A2 inhibitor, concomitant use with CYP1A2 substrates (e.g. haloperidol) may lead to altered plasma concentrations of these substrates. 14, 15 Dabrafenib. Dabrafenib is a BRAF inhibitor used in the treatment of advanced melanoma and NSCLC. Dabrafenib was shown to be a substrate for P-gp and BCRP. Since the bioavailability of dabrafenib is high (95%), only limited pharmacokinetic effects can be expected with inhibitors and inducers of these drug transporters. Dabrafenib is metabolized by both CYP3A4 (24%) and CYP2C8 (67%). Administration of dabrafenib with ketoconazole, gemfibrozil (a CYP2C8 inhibitor), and rifampicin showed significant changes in AUC, however these effects were mostly relatively small. 14, 15 Furthermore, dabrafenib is known to auto-induce CYP3A4 mediated metabolism. 14, 15 In conclusion, concomitant administration with strong CYP3A4 and CYP2C8 inhibitors or inducers must be avoided. Furthermore, a study with warfarin showed a 37% and 33% decrease in AUC and an 18% and 19% decrease in C max for S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4/CYP1A2 substrate), respectively. 78 Therefore, dabrafenib is characterized as a moderate CYP3A4 inducer and a weak CYP2C9 inducer and as a result concomitant use of substrates for these enzymes must be avoided. 78 Ibrutinib. Ibrutinib is used as treatment for chronic lymphatic leukemia (CLL) and mantle cell lymphoma. Ibrutinib is an inhibitor of P-gp and BCRP. 14, 15 Ibrutinib is mainly metabolized by CYP3A4. Ketoconazole gave 2800% and 2300% increase in C max and AUC respectively. 14, 15, 51 Furthermore concomitant administration with rifampicin showed 92% and 90% decrease in C max and AUC respectively. 14, 15 Administration with a moderate inhibitor of CYP3A4 (e.g. erythromycin) led to 240% and 200% increase in C max and AUC respectively. 14, 15, 82 Overall concomitant administration with strong CYP3A4 inhibitors or inducers must be avoided. If ibrutinib is administered with moderate and strong CYP3A4 inhibitors the ibrutinib dose should be reduced to 280 mg and 140 mg respectively. When ibrutinib is administered with substrates of P-gp and BCRP monitoring of side effects of these substrates is warranted. When toxicity appears the dose of these substrates may be decreased.
Lenvatinib. Lenvatinib is used in the treatment of RCC and advanced thyroid carcinoma. It was shown to be a MDR1 substrate, a P-gp and BCRP substrate and inhibitor and an OATP1B3 inhibitor in vitro. 14, 15 When lenvatinib is administered with ketoconazole or rifampicin, only marginal changes in AUC and C max were observed. 54, 55 Since lenvatinib is mainly metabolized through several phase II mechanisms (e.g. aldehyde oxidase and glutathione conjugation) into less active metabolites and only for a small part by CYP3A4, these changes were most likely due to an journals.sagepub.com/home/tam 27 interaction with P-gp. 14, 15 Lenvatinib has an overall low DDI potential and dose modifications are currently not considered necessary.
Nintedanib. Nintedanib is used in the treatment of NSCLC. It is a substrate and weak inhibitor of P-gp. 14, 15, 94 When nintedanib is administered with a strong P-gp inhibitor, a 100 mg (25%) step-wise daily dose reduction must be considered with close monitoring of side effects. Use of strong P-gp inducers must be avoided, since nintedanib plasma concentrations may decrease. Nintedanib is mainly metabolized due to hydrolysis by esterases and glucuronidated by UGT with only a minor involvement of CYP enzymes (CYP3A4; 5%). 14, 15 Administration with ketoconazole resulted in 61% and 83% increase in AUC and C max respectively and administration with rifampicin demonstrated a decrease in AUC of 50% and 60% of C max respectively. 42 These differences were probably due to a DDI with P-gp. Therefore, concomitant administration with strong inhibitors or inducers of CYP3A4 is considered safe.
Osimertinib. Osimertinib is used in the treatment of NSCLC. 14, 15 Osimertinib is a substrate and inhibitor for P-gp and BCRP. 14,15 A study with rosuvastatin (a sensitive BCRP substrate) showed an increase in AUC and C max of 35% and 72% of rosuvastatin respectively. 87 Osimertinib is mainly metabolized by CYP3A4 and CYP3A5, but only rifampicin resulted in a significant change in both AUC and C max in contrast to itraconazole. 86 A study with simvastatin (a CYP3A4 substrate) resulted in a slight decrease in AUC and C max of simvastatin of 9% and 23%, but these changes are not considered to be of clinical significance. 87 In conclusion only strong CYP3A4 inducers must be used with caution and close monitoring of side effects of osimertinib is warranted.
Ponatinib. Ponatinib is used in the treatment of CML and Acute lymphatic leukemia (ALL). Ponatinib is a substrate and inhibitor of P-gp and BCRP. 14, 15 Therefore, concomitant use of ponatinib with strong inhibitors or inducers of these transporters should be avoided. Ponatinib is mainly metabolized into nonactive metabolites by CYP3A4 and to a lesser extent by CYP2D6, CYP2C8 and CYP3A5. 14, 15 A study with concomitant ketoconazole administration showed an increase in C max of 47% and 78% in AUC of ponatinib. 88 Multiple dosing of rifampicin demonstrated a decrease in AUC and C max of 42% and 62% respectively. 89 As a consequence, concomitant administration with inhibitors of CYP3A4 and P-gp should be avoided or a dose reduction to 30 mg should be applied when administered concomitantly. Moreover, the use of strong CYP3A4 or P-gp inducers must be avoided or duration must be minimized, since ponatinib exposure may change.
Tivozanib. Tivozanib is used in the treatment of RCC. Tivozanib is an inhibitor of BCRP and is metabolized by multiple liver enzymes, including CYP3A4, CYP1A1 and several UGT1A enzymes (e.g. UGT1A1, UGT1A3 and UGT1A7). 14,15 A study with rifampicin showed a 52% decrease in tivozanib AUC. Therefore, the administration with strong CYP3A4 inducers should be avoided. A dose escalation is not necessary since the effect on tivozanib exposure is relatively small. Ketoconazole did not result in significant changes in tivozanib exposure. 14, 15, 91 Administration with strong CYP3A4 inhibitors is therefore considered safe. Furthermore, the concomitant administration with strong UGT inhibitors or inducers (e.g. probenecid or ibuprofen) should be avoided since tivozanib plasma concentrations potentially may change.
Trametinib. Trametinib is used in the treatment of melanoma and NSCLC. It is a known inhibitor of P-gp, BCRP, OAT1, OAT3, OATP1B1, OATP1B3, OAT2B1, OCT2 and MATE1 and a substrate for P-gp. 14, 15 As a result, the use of strong inhibitors or inducers of P-gp (e.g. ketoconazole) must be avoided. Trametinib is metabolized through deacetylation, oxidation and glucuronidation pathways. 14, 15 No drug interaction studies are available to date, however since trametinib is not dependent on CYP isoenzymes, no DDIs with CYPs are to be expected.
DDI studies with longer available MKIs
In recent years several new studies have been published that investigated DDIs with longer available MKIs. Most of these studies are listed in Tables 1-3 . There are only a few clinical DDI studies concerning drug transporters, since most studies mainly focus on CYP interactions. A phase I study investigated the combination of gefitinib and irinotecan and found an increase in SN-38 (the active irinotecan metabolite) and irinotecan plasma exposure, attributed to an enhanced BCRP activity in the gut. 50 Moreover, in patients using sorafenib with rifampicin, the concentration of the metabolite sorafenibglucuronide increased, suggesting inhibition of 28 journals.sagepub.com/home/tam OATP1B1 by rifampicin and confirms sorafenib as an OATP1B1 substrate. 57 Several new studies investigated possible DDIs regarding drug metabolism. For a complete overview see Table 3 . For example: imatinib coadministration caused a 26% increase in cyclosporine (CYP3A4 and CYP2C8 substrate) plasma levels, explained by CYP3A4 inhibition by imatinib. 69 In addition, lapatinib and pazopanib demonstrated an increase of 23% and 26% in paclitaxel AUC respectively, suggesting inhibition of CYP2C8 by these MKIs. 83, 95 Furthermore, regorafenib significantly increased the exposure to irinotecan and its active metabolite SN-38 due to UGT1A1 inhibition. 96, 97 Although most MKIs are metabolized through CYP enzymes it becomes more apparent that MKI metabolism is multifactorial and the inhibition and induction of other pathways (such as drug transporters) may also significantly influence MKI exposure. More research is needed to fully assess the DDI potential of these new pathways and their clinical relevance.
Discussion
Many MKIs have a narrow therapeutic window, with a clear relation between exposure and response on one hand and toxicity on the other. 98 For example, sunitinib and pazopanib show increasing severe toxicity with raising plasma concentration, leading to dose reductions and discontinuation of treatment in many patients. 99, 100 Meanwhile, a threshold for efficacy for these drugs is seen. [98] [99] [100] Therefore, it is important to provide the right dose for the individual patient, in order to optimize treatment efficacy and minimize toxicity. To accomplish this, there is a shifting paradigm towards personalized dosing in oncology practice. 5 Along with other factors, DDIs are key factors influencing MKI exposure and subsequent clinical outcome. In addition, cancer patients are at greater risk for DDIs. 7 Therefore, a structured medication review for clinically relevant DDIs should take place on a regular basis.
To create a solid base for medication review, more DDI studies are strongly needed and results should be weighed on their clinical relevance. Specific and practical guidelines must be developed to guide clinicians and pharmacists in the management of DDIs in clinical practice. A practical way to reach this goal is by establishing clinical expert groups for consensus-based evaluation of clinical significance and management of the DDIs. 101 ASAs may strongly decrease MKI bioavailability.
Since there is no clear general consensus on the management of this DDI we presented a practical advice for all ASAs. However, another problem is that there is no standard design for clinical DDI research with ASAs. Ideally, drug exposure should be compared in a crossover design between MKI monotherapy and during co-administration of the strongest ASA [e.g. the PPI esomeprazole (40 mg)] 3 h prior to MKI administration, since maximum intragastric pH elevating effect of this PPI is reached after this time period. 38 In that case, when no effects are seen, a DDI between MKIs and PPIs can be ruled out. When a significant DDI with H 2 -antagonists and antacids is expected, a corresponding treatment arm may be added. A more standardized study design of these ASA-DDI studies may provide a solid basis for practical management of this DDI, since study results could more easily be interpreted and compared between different MKIs.
Drug transporters are located throughout the body and thus potentially influence pharmacokinetics on multiple levels. 39 To date, insufficient attention has been given to the clinical relevance of these DDIs concerning drug transporters. Unfortunately, there is a lack of clinical studies investigating this type of DDI. Furthermore, many registration studies use ketoconazole or rifampicin as an inhibitor or inducer of CYP3A4, but these drugs are also strong inhibitors or inducers of P-gp. As a result, the P-gp effect may be underestimated or overestimated in the assessment reports. More research is needed to fully assess the DDI potential concerning drug transporters.
In contrast, DDIs with drug transporters may also be used for beneficial purposes. For instance, inhibition of certain drug transporters (e.g. P-gp) in the blood-brain barrier might theoretically lead to altered blood-brain barrier penetration, which may result in better brain (metastasis) penetration of a MKI, for example, osimertinib. 102 In addition, Zimmerman and colleagues demonstrated a protective effect on hand-foot skin reaction in mice, a frequently seen side effect of sorafenib, when sorafenib was concomitantly taken with the OAT6 inhibitor probenecid. 103
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Furthermore erlotinib may reduce cisplatin toxicity (e.g. nephrotoxicity and ototoxicity) through OCT2 inhibition. 48 Such potentially useful applications of DDIs between MKIs and drug transporters need to be further explored, and may in the future result in more effective MKI therapy.
In current DDI research there is a trend towards a model-based DDI prediction, like the PBPKmodels. 104, 105 PBPK-models are multi-compartmental (often represented as single organs or tissues) models which use (in vitro) pharmacokinetic data and human physiologically-dependent system parameters to predict DDIs with a mathematical model. 106 A disadvantage of PBPK modeling is the lack of sufficient in vivo data that adds to the uncertainty in the predictions of the PBPK model. Also, the lack of knowledge regarding multifactorial physiologic changes in, for instance, enzyme and transporter expression and activity might be a possible confounding factor. Despite the evident benefits of PBPK modeling in current DDI research, confirmatory evidence from clinical trials in humans is needed to assess a good predicting model. 105 Another novel approach in oncology in managing DDIs is therapeutic drug monitoring (TDM). For many MKIs there is a clear relationship between exposure, toxicity and treatment efficacy (e.g. imatinib, pazopanib and sunitinib). 98, 100, 107 For some MKIs TDM could be an alternative way to manage DDIs in MKI therapy, where dose adjustments can be made if plasma levels are outside the therapeutic range. Furthermore, TDM has the advantage of monitoring MKI treatment, continuously over a longer time period which may result in better therapy efficacy. However, further research is needed to confirm the clinical relevance of TDM as a tool in DDI management.
In conclusion, most MKIs are highly prone to cause DDIs. Drugs that elevate intragastric pH, strong inhibitors or inducers of CYP enzymes and drug transporters can result in clinically relevant changes in MKI exposure. For many DDIs the only evidence for a potential DDI comes from in vitro data or is predicted based on PBPK modeling. Without clinical data it is difficult to determine the exact clinical relevance of these possible DDIs. In this review, we present practical recommendations for management of MKI interactions in clinical practice. Acknowledging these DDIs by clinicians may eventually result in a more personalized and effective treatment with MKIs.
